Servicios Personalizados
Revista
Articulo
Indicadores
- Citado por SciELO
- Accesos
Links relacionados
- Similares en SciELO
Compartir
Revista alergia México
versión On-line ISSN 2448-9190
Resumen
FRAGA-OLVERA, Alira; SAAVEDRA-SALINAS, Miguel Ángel; BELTRAN-MENDOZA, Jesus Quetzalcoatl y MENDIETA-FLORES, Elizabeth. Prevalence of persistent hypogammaglobulinemia in patients with autoimmune rheumatic disease who received treatment with Rituximab in a national medical center in Mexico. Rev. alerg. Méx. [online]. 2022, vol.69, n.4, pp.171-182. Epub 25-Ago-2023. ISSN 2448-9190. https://doi.org/10.29262/ram.v69i4.1142.
Objective:
To describe the prevalence of persistent hypogammaglobulinemia in patients receiving Rituximab as a treatment for autoimmune rheumatological diseases.
Methods:
A transversal, retrospective and unicentric study, carried out in patients with autoimmune rheumatic diseases who were admitted to the Rheumatology service of the Hospital de Especialidades Dr. Antonio Fraga Mouret, Centro Médico Nacional La Raza, Mexico City, to receive treatment with rituximab between January 2013 and January 2018. Descriptive and inferential statistics of serum levels of immunoglobulins, clinical-demographic characteristics, diagnosis, and treatment received were performed.
Results:
from 262 patients with autoimmune rheumatological disease who received treatment with Rituximab; We identified 8 patients with persistent hypogammaglobulinemia (6 women and 2 men), this is a prevalence of 3.1%. No associated factors with the development of hypogammaglobulinemia were identified.
Conclusions:
Until now, no associated prognostic or predictive factors have been identified with persistent hypogammaglobulinemia. Additional prospective studies are required to understand more precisely the implications of persistent hypogammaglobulinemia in patients with autoimmune diseases.
Palabras llave : Persistent hypogammaglobulinemia; Rheumatologic autoimmune disease; Immunoglobulins; Rituximab.